ABBV · ABBVIE INC. · Top AI ETF

Back to holdings

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer.

Close · 3M

+30.95%

Held by 2 AI ETFs

PQUS0.310%

as of Sep 1

LQAI0.130%

as of Sep 2

Signal performance

Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.

Buy signals13

Win rate92% (12/13)

Avg buy return+8.48%

PQUSnow 0.310% of fund14 signals

PQUS · Weight decrease · 2d

weight 0.330% → 0.310% (-0.020 pp)·stock down 0.7% in the 30 days before

Aug 29·entry $256.42·now $260.21

+1.48%

since Aug 29

PQUS · Weight increase · 2d

weight 0.570% → 0.600% (+0.030 pp)·stock up 3.4% in the 30 days before

Aug 20·entry $261.83·now $260.21Fresh

-0.62%

since Aug 20

PQUS · Weight increase · 2d

weight 0.600% → 0.620% (+0.020 pp)·stock up 2.7% in the 30 days before

Aug 13·entry $250.82·now $260.21Drifting

+3.74%

since Aug 13

PQUS · Weight decrease · 2d

weight 0.640% → 0.600% (-0.040 pp)·stock down 1.5% in the 30 days before

Aug 7·entry $246.04·now $260.21

+5.76%

since Aug 7

PQUS · Weight decrease · 2d

weight 0.690% → 0.640% (-0.050 pp)·stock down 0.0% in the 30 days before

Aug 2·entry $245.10·now $260.21

+6.16%

since Aug 2

PQUS · Weight increase · 2d

weight 0.670% → 0.690% (+0.020 pp)·stock down 0.0% in the 30 days before

Jul 31·entry $250.94·now $260.21Drifting

+3.69%

since Jul 31

PQUS · Weight increase · 2d

weight 0.630% → 0.670% (+0.040 pp)·stock up 14.4% in the 30 days before

Jul 19·entry $253.38·now $260.21Drifting

+2.70%

since Jul 19

PQUS · Weight decrease · 2d

weight 0.650% → 0.630% (-0.020 pp)·stock up 14.4% in the 30 days before

Jul 17·entry $254.49·now $260.21

+2.25%

since Jul 17

PQUS · Weight decrease · 2d

weight 0.670% → 0.640% (-0.030 pp)·stock up 10.1% in the 30 days before

Jul 12·entry $248.00·now $260.21

+4.92%

since Jul 12

PQUS · Weight increase · 2d

weight 0.640% → 0.690% (+0.050 pp)·stock up 17.6% in the 30 days before

Jun 28·entry $254.31·now $260.21Drifting

+2.32%

since Jun 28

PQUS · Weight increase · 2d

weight 0.820% → 0.910% (+0.090 pp)·stock up 14.1% in the 30 days before

Jun 25·entry $243.14·now $260.21Drifting

+7.02%

since Jun 25

PQUS · Weight increase · 2d

stock up 1.3% in the 30 days before

Jun 19·entry $230.01·now $260.21Chased

+13.13%

since Jun 19

PQUS · Weight decrease · 2d

stock up 9.2% in the 30 days before

Jun 13·entry $221.59·now $260.21

+17.43%

since Jun 13

PQUS · Weight increase · 2d

stock up 10.8% in the 30 days before

Jun 7·entry $223.07·now $260.21Chased

+16.65%

since Jun 7

LQAInow 0.130% of fund1 signal

LQAI · New entry · 1d

weight 0 → 0.120% (new)·stock down 3.5% in the 30 days before

Aug 6·entry $243.87·now $260.21Drifting

+6.70%

since Aug 6

AIEQno longer held6 signals

AIEQ · Exit · 1d

weight 0.050% → 0 (exited)·stock up 6.1% in the 30 days before

Sep 1·entry $259.99·now $260.21

+0.08%

since Sep 1

AIEQ · Weight decrease · 2d

weight 1.180% → 0.050% (-1.130 pp)·stock up 17.9% in the 30 days before

Jul 1·entry $251.06·now $260.21

+3.64%

since Jul 1

AIEQ · Weight increase · 2d

weight 1.090% → 1.180% (+0.090 pp)·stock up 17.6% in the 30 days before

Jun 28·entry $254.31·now $260.21Drifting

+2.32%

since Jun 28

AIEQ · Weight increase · 2d

stock up 1.3% in the 30 days before

Jun 18·entry $216.49·now $260.21Chased

+20.19%

since Jun 18

AIEQ · Accumulation · 5d

stock up 8.1% in the 30 days before

Jun 11·entry $224.77·now $260.21Chased

+15.77%

since Jun 11

AIEQ · Weight increase · 3d

stock up 10.8% in the 30 days before

Jun 7·entry $223.07·now $260.21Chased

+16.65%

since Jun 7

Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.

Buffett-style framework

Too hard to callas of Aug 30

AI ETFs are currently holding AbbVie, with one fund showing mixed signals of both increasing and decreasing weight trends. This stands in contrast to the value-investing framework's verdict, which finds AbbVie too complex to reliably project cash flows, thus declining further analysis.

Circle of CompetenceThe biotechnology industry's reliance on patent cycles and continuous R&D for blockbuster drugs makes ten-year cash flow projections genuinely unpredictable within this framework.
Economic MoatAnalysis of economic moat is not conducted as the business is deemed outside the circle of competence.
ManagementAnalysis of management is not conducted as the business is deemed outside the circle of competence.
Financial HealthAnalysis of financial health is not conducted as the business is deemed outside the circle of competence.
Margin of SafetyAnalysis of margin of safety is not conducted as the business is deemed outside the circle of competence.

AbbVie operates in the biotechnology sector, an industry characterized by unpredictable patent expirations and intense R&D demands, which makes projecting long-term owner earnings highly challenging. Consequently, the company falls outside the required circle of competence for this value-investing framework, precluding a full assessment.

Educational interpretation generated by AI applying frameworks Warren Buffett documented in his shareholder letters and other public writings. Not a statement by Mr. Buffett or Berkshire Hathaway, and not investment advice.